2. Search Result
Search Result
Results for "

non-Hodgkin lymphomas

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

14

Inhibitory Antibodies

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-146237
    Golcadomide

    CC-99282

    		 Ligands for E3 Ligase Molecular Glues Cancer
    Golcadomide (CC-99282) is a potent and orally active cereblon (CRBN) E3 ligase modulator (CELMoD). Golcadomide co-opts CRBN to induce potent and targeted degradation of Ikaros and Aiolos. Golcadomide can be used for researching non-Hodgkin lymphomas .
    Golcadomide
  • HY-P99056
    Utomilumab

    PF 05082566

    		 TNF Receptor Inflammation/Immunology Cancer
    Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20 + non-Hodgkin lymphomas (NHL) .
    Utomilumab
  • HY-10293
    Aderbasib

    INCB007839; INCB7839

    		 MMP Cancer
    Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2 + breast cancer, gliomas, et al .
    Aderbasib
  • HY-149221
    Apoptosis inducer 11

    		Apoptosis Cancer
    Apoptosis inducer 11 (compound 3u) induces apoptosis through the mitochondrial pathway. Apoptosis inducer 11 induces a block in G2/M, a strong decrease in S phase in non-Hodgkin lymphoma cell lines .
    Apoptosis inducer 11
  • HY-P99230
    Pinatuzumab

    		Integrin CD22 Cancer
    Pinatuzumab is a CD22 monoclonal antibody. Pinatuzumab targets the cell-surface antigen CD22. Pinatuzumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including non-Hodgkin lymphoma (NHL) .
    Pinatuzumab
  • HY-P99224
    Veltuzumab

    IMMU-106; hA20

    		 Integrin Cancer
    Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .
    Veltuzumab
  • HY-P99264
    Inotuzumab

    Humanized Anti-CD22 Recombinant Antibody

    		 ADC Antibody CD22 Cancer
    Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
    Inotuzumab
  • HY-158105
    ARV-393

    		PROTACs BCL6 Cancer
    ARV-393 is an orally active PROTAC that utilizes the ubiquitin-proteasome system to target the degradation of BCL6. ARV-393 consists of ligand conjugates targeting BCL6 and the E3 ligase cereblon, respectively. ARV-393 has DC50 and GI50 values of <1 nM in multiple cell lines of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). ARV-393 also demonstrated considerable tumor suppressor activity in tumor xenograft models. ARV-393 is being studied to inhibit non-Hodgkin lymphoma.
    ARV-393
  • HY-P99656
    Iladatuzumab

    MCDS0593A

    		 ADC Antibody Cancer
    Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
    Iladatuzumab
  • HY-P9910
    Obinutuzumab

    GA101; Anti-Human CD20 type II, Humanized Antibody

    		 CD20 Cancer
    Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
    Obinutuzumab
  • HY-P99033
    Mosunetuzumab

    BTCT-4465A

    		 CD20 CD3 Inflammation/Immunology Cancer
    Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .
    Mosunetuzumab
  • HY-P99711
    Loncastuximab

    RB4v1.2

    		 CD19 Cancer
    Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) .
    Loncastuximab
  • HY-P99952
    Ripertamab

    SCT400

    		 CD20 Cancer
    Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) .
    Ripertamab
  • HY-P99464
    Bectumomab

    IMMU-LL 2

    		 CD22 Cancer
    Bectumomab (IMMU-LL 2) is an humanized IgG2a mAb against human CD22 (antigen). Bectumomab is also an anti-lymphoma antibody fragment. Bectumomab can be used for imaging in combination with technetium 99 (Tc99m LL2 Fab). Moreover, Bectumomab examines in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) and to assess targeting before radioimmunoresearch (RIT) .
    Bectumomab
  • HY-P99289
    Epratuzumab

    Antibody hLL 2; Anti-Human CD22 Recombinant Antibody

    		 CD22 Inflammation/Immunology Cancer
    Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
    Epratuzumab
  • HY-12908
    Bcl-xL antagonist 2

    Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-XL with an IC50 and Ki of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) .
    Bcl-xL antagonist 2
  • HY-13617
    Edatrexate

    CGP 30694

    		 Antifolate Cancer
    Edatrexate (CGP 30694), as known as 10-Ethyl-10-deazaaminopterin, is Methotrexate (HY-14519) analog, exhibits antitumor activity against MTX-resistant tumors. Edatrexate is an antifolate antimetabolite, can be used for reasearch of non-small-cell lung cancer, breast cancer, non-Hodgkin's lymphoma, and cancer of the head and neck .
    Edatrexate
  • HY-13062
    Daunorubicin hydrochloride
    Maximum Cited Publications
    22 Publications Verification

    Daunomycin hydrochloride; RP 13057 hydrochloride; Rubidomycin hydrochloride

    		 Topoisomerase DNA/RNA Synthesis ADC Cytotoxin Bacterial Autophagy Apoptosis Antibiotic Infection Neurological Disease Cancer
    Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin hydrochloride is also an anthracycline antibiotic. Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor .
    Daunorubicin hydrochloride
  • HY-13062A
    Daunorubicin

    Daunomycin; RP 13057; Rubidomycin

    		 Topoisomerase DNA/RNA Synthesis ADC Cytotoxin Autophagy Bacterial Antibiotic Apoptosis Infection Neurological Disease Cancer
    Daunorubicin (Daunomycin) is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin inhibits DNA and RNA synthesis. Daunorubicin is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin is also an anthracycline antibiotic. Daunorubicin can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor .
    Daunorubicin
  • HY-106634
    Mitoguazone
    1 Publications Verification

    Methylglyoxal-bis(guanylhydrazone); MGBG; Methyl-GAG

    		 HIV Apoptosis Infection Cancer
    Mitoguazone (Methylglyoxal-bis(guanylhydrazone)) is a synthetic polycarbonyl derivative with potent antineoplastic activity. Mitoguazone is a brain-penetrant and competitive S-adenosyl-methionine decarboxylase (SAMDC) inhibitor that disrupts polyamine biosynthesis. Mitoguazone induces cell apoptosis. Mitoguazone inhibits HIV DNA integration into the cellular DNA in both monocytes and macrophages. Mitoguazone has the potential for acute leukemia, Hodgkin's and non-Hodgkin's lymphoma treatment .
    Mitoguazone
  • HY-108876
    Daunorubicin citrate

    Daunomycin(citrate); RP 13057(citrate); Rubidomycin(citrate)

    		 Topoisomerase DNA/RNA Synthesis ADC Cytotoxin Autophagy Bacterial Antibiotic Apoptosis Infection Neurological Disease Cancer
    Daunorubicin (Daunomycin) citrate is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin citrate inhibits DNA and RNA synthesis. Daunorubicin citrate is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin citrate is also an anthracycline antibiotic. Daunorubicin citrate can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor .
    Daunorubicin citrate
  • HY-P99272
    Ulocuplumab

    BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody

    		 CXCR Cancer
    Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .
    Ulocuplumab
  • HY-109585
    IRAK4-IN-7

    		IRAK Inflammation/Immunology Cancer
    IRAK4-IN-7 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment .
    IRAK4-IN-7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: